NasdaqCM - Nasdaq Real Time Price • USD
ASLAN Pharmaceuticals Limited (ASLN)
As of 10:18 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.61 | -0.45 | -3.34 | -2.35 |
| Low Estimate | -0.61 | -0.45 | -3.34 | -2.35 |
| High Estimate | -0.61 | -0.45 | -3.34 | -2.35 |
| Year Ago EPS | -1.29 | -0.11 | -2.69 | -3.34 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | 12M | 12M | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -4.05 | -0.8 | -0.78 | -0.65 |
| EPS Actual | -1.29 | -0.11 | -0.56 | -0.78 |
| Difference | 2.76 | 0.69 | 0.22 | -0.13 |
| Surprise % | 68.10% | 86.20% | 28.20% | -20.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.61 | -0.45 | -3.34 | -2.35 |
| 7 Days Ago | -0.61 | -0.54 | -3.62 | -2.42 |
| 30 Days Ago | -0.6 | -0.53 | -3.48 | -1.3 |
| 60 Days Ago | -0.6 | -0.53 | -3.48 | -1.3 |
| 90 Days Ago | -0.63 | -0.67 | -4.25 | -1.3 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | -- | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ASLN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 52.70% | -- | -- | 8.30% |
| Next Qtr. | -309.10% | -- | -- | 11.90% |
| Current Year | -24.20% | -- | -- | 5.60% |
| Next Year | 29.60% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -- | -- | -- | 11.05% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/3/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/15/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/18/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 3/13/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/11/2024 |
Related Tickers
TCON TRACON Pharmaceuticals, Inc.
2.0471
+1.34%
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.7000
0.00%
TERN Terns Pharmaceuticals, Inc.
5.96
+1.19%
RVPHW Reviva Pharmaceuticals Holdings, Inc.
0.3500
+9.38%
NRXP NRx Pharmaceuticals, Inc.
2.9950
+0.17%
EYEN Eyenovia, Inc.
0.8285
+1.57%
ADIL Adial Pharmaceuticals, Inc.
1.4098
-2.44%
CNTB Connect Biopharma Holdings Limited
1.4500
+3.57%
ALZN Alzamend Neuro, Inc.
0.5100
+0.99%
RNAZ TransCode Therapeutics, Inc.
0.7650
+23.31%